Senti Biosciences, INC Form 4 insider transactions

Kanya Rajangam, President & Chief Medical & Development Officer of Senti Biosciences, reported a disposition of 1,384 common shares for tax withholding purposes.

Senti Biosciences CEO Timothy K Lu reported a tax-related disposition of 4,191 common shares to cover restricted stock unit vesting obligations, not an open market sale.

Senti Biosciences, Inc. Director Bryan Daniel Baum was granted 43,900 stock options with an exercise price of $1.95, vesting over three years starting July 18, 2025.

Senti Biosciences, Inc. Director James J. Collins was granted 21,950 stock options with an exercise price of $2.05, vesting over time.

Senti Biosciences, Inc. Director Feng Hsiung was granted 21,950 stock options with an exercise price of $2.05, vesting over one year or by the 2026 Annual Meeting, as disclosed in a recent SEC Form 4 filing.

Senti Biosciences, Inc. Director Fran Schulz was granted 21,950 stock options with an exercise price of $2.05, aligning her interests with shareholder value.

Senti Biosciences, Inc. Director Brenda Cooperstone was granted 21,950 stock options with an exercise price of $2.05, vesting over one year or by the 2026 Annual Meeting.

Senti Biosciences, Inc. Director Donald F. Tang was granted 21,950 stock options with an exercise price of $2.05, aligning his interests with shareholder value.

Senti Biosciences, Inc. Director and 10% Owner Edward T. Mathers was granted 21,950 stock options with an exercise price of $2.05, vesting over one year or by the 2026 Annual Meeting.

Celadon Partners SPV 24, a 10% owner of Senti Biosciences, converted its Series A Convertible Preferred Stock into 9,777,000 shares of Common Stock on March 10, 2025.

New Enterprise Associates 15, L.P. converted its Series A Convertible Preferred Stock into 3,333,000 shares of Common Stock in Senti Biosciences on March 10, 2025.

Bayer Healthcare LLC converted its Series A Convertible Preferred Stock into 2,222,000 shares of Senti Biosciences common stock following stockholder approval.

Director Edward T. Mathers acquired stock options in Senti Biosciences, Inc. on March 7, 2025.

Kanya Rajangam, a top executive at Senti Biosciences, acquired 33,000 shares of common stock through the conversion of Series A Convertible Preferred Stock.

Director Fran Schulz acquired 43,900 stock options in Senti Biosciences on March 7, 2025, at an exercise price of $3.52.

Director James J. Collins acquires stock options in Senti Biosciences.

Director Donald F Tang of Senti Biosciences acquired stock options for 43,900 shares at an exercise price of $3.52 on March 7, 2025.

Director Brenda Cooperstone reports acquisition of 43,900 Senti Biosciences stock options on March 7, 2025.

Director Feng Hsiung of Senti Biosciences acquired stock options for 43,900 shares of common stock on March 7, 2025.

John Harry Cross III, CFO of Senti Biosciences, acquired stock options for 174,200 shares at an exercise price of $3.52 on March 7, 2025.

Kanya Rajangam, Pres. & Chief Med. & Dev. Off. of Senti Biosciences, reports acquisition of shares and options in the company.

CEO Timothy Lu reports transactions involving Senti Biosciences' common stock and stock options, including the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Senti Biosciences CEO Timothy Lu sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Kanya Rajangam, Pres. & Chief Med. & Dev. Off. of Senti Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Bayer Healthcare LLC and related entities have reported the acquisition of Senti Biosciences Series A Convertible Preferred Stock and warrants, convertible into millions of common shares.

Senti Biosciences director Donald F. Tang acquired 12,500 stock options on December 9, 2024, which vest over three years.

Director Fran Schulz of Senti Biosciences acquired 12,500 stock options on December 9, 2024, which vest over three years.

A Form 4 filing reveals Senti Biosciences' President and Chief Medical and Development Officer's transactions involving Series A Preferred Stock, Common Stock, and warrants.

Director Edward T. Mathers acquired stock options for 62,500 shares of Senti Biosciences at an exercise price of $0.31 on July 10, 2024.

Director Omid Farokhzad acquired 62,500 stock options in Senti Biosciences on July 10, 2024.